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Patient status on study completion (n=75) n (%)
PHQ9 and/or GAD7 scores reduced by 50% 34 (45.3)
PHQ9 and/or GAD7 scores not reduced by 50% 5 (6.7)
Lost to follow up 16 (21.3) 
Appointment times not convenient so could 
not attend 3 (4.0)
Referred to GP for onward referral to CMHT 3 (4.0)
Referred to GP as physical health issue more 
dominant 3 (4.0)
Psychotropic treatment not needed 3 (4.0)
Appointments cancelled 2 (2.7) 
Psychology/ cognitive behavioural therapy to 
be commenced 2 (2.7)
Follow-up by psychiatrist/ community 
psychiatric nurse 2 (2.7)
Could not complete PHQ9 and/or GAD7 2 (2.7)
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75 (84.3%) of the 89 patients referred attended their first consultation. Around two thirds of patients (n=47, 62.7%) were referred with a diagnosis of mixed depression and
anxiety. Mean patient age (SD) was 40.1 years (13.9), just under two thirds (n=49, 65.3%) being female. 324 consultations were held (median 3, IQR 2-5, range 1-14).
QUANTITATIVE RESULTS
SERVICE AIM & OBJECTIVES
To improve the pharmaceutical care delivered to patients with depression and/or 
anxiety in primary care by:
• providing evidence based psychopharmacological interventions
• evidence based prescribing in line with NHS Highland Formulary
• MDT working within primary care, and liaison with CMHTs and secondary care
• reducing GP workload relating to the treatment of mental health disorders
RESEARCH QUESTIONS
Multi-perspective evaluation of the pilot:
Phase 1 Quantitative - Level of uptake, pharmaceutical care issues identified, resultant 
actions and outcomes
Phase 2 Qualitative - Views and experiences of patients and the healthcare team
QUALITATIVE INTERVIEWS WITH STAFF
In the analysis4 of staff interviews (n=8)
three key themes were identified:
Integration
• openness and willingness to change
• perception of benefits
• positive acceptance of the service
Enablers
• enhancement of service provision
• key stakeholder engagement
Barriers
• space at GP practice
• potential reluctance of staff
• access to systems and supports
The pharmacist put me at ease very quickly and I very much felt part of 
the discussion  we had in how to proceed with my treatment. My last 
appointment with the pharmacist  was to discuss how well my medication 
was working and how she fully explained that  if there were any changes 
to how I felt to return to my GP to discuss this from my  perspective. A 
very valuable and necessary service run alongside General Practice.
I feel it is much 
needed but more 
people should be 
aware of its 
availability.  The 
continuity it was 
providing me was 
crucial to my 
recovery/progress.  
Simply having that 
one continual person 
treating me made a 
huge difference. 
At first I was wary of seeing the pharmacist.  I had doubts of her knowledge 
but after 15 minutes my mind was put at ease as she clearly understood 
the problems I was facing.  During all my consultations [name] fully 
explained what drugs she was prescribing and why .....  I would recommend 
that a trained pharmacist be put into medical centres as I am truly grateful 
for her help and time given to me.
I immediately  felt 
comfortable with the 
pharmacist. She 
explained in detail her 
role and I felt able to 
open up to her quite 
quickly.  I didn’t feel at 
any time under pressure 
to end our discussions.
Just one comment: [name]
was brilliant!
QUALITATIVE INTERVIEWS WITH PATIENTS
STORM
The Decider
Alcohol Brief 
Intervention
Vision
BACKGROUND
Mental health issues are a common feature of primary care consultations and around a
third of GP consultations have a mental health element.1 The Scottish Government’s 10
year Mental Health Strategy has ambitions to transform services so every GP practice
has multi-disciplinary teams (MDTs) who can support and treat patients with mental
health issues while ensuring good communication with community mental health teams
(CMHT) and secondary care services.1
Despite these strategic plans, there is currently a lack of specialist mental health clinical
pharmacist prescriber input to the care of patients with mental health issues within
general practice in NHS Highland.1,2 A 12 month pilot, funded by the Scottish
Government’s Primary Care Transformation Fund, has been conducted during which
two specialist mental health clinical pharmacist prescribers consulted with patients with
depression and anxiety by appointment at one of two GP Practices in NHS Highland.
15 of the 70 patients mailed the questionnaire responded (response rate 21.4%). Almost all patient responding to items in the
CARE measure3 gave a rating of excellent or very good across all items. All responses were positive when rating aspects of the
pharmacist consultations and attitudinal statements with only 2 patients preferring to consult a GP rather than a pharmacist, and
almost three quarters were more interested in quality of care rather than who delivered the care.
0 5 10 15 20 25 30
Monitor response to treatment
Lack of effectiveness, review antidepressant
New presentation, discuss choice of treatment
Unable to tolerate, review antidepressant
Stop antidepressant
Reasons for patient referral to pharmacists (n=75)
DISCUSSION AND CONCLUSION
Even when considering the evaluation limitations, it is clear that this pilot study has been successful. All four service objectives
were met either fully or partially. Responses to the patient survey were overwhelmingly positive. Written comments from patients
were highly appreciative of the pharmacists and the impact of the service on their mental health. Analysis of interviews with the
members of the MDT and the pharmacists identified that the service had been well-integrated within primary care, leading to key
perceived benefits for patients and the MDT. The only negative comments were around barriers to implementation which are to be
expected when setting up a new service. In conclusion, the evaluation has identified that the pilot was successful from a number of
key perspectives. These results should be considered in planning further mental health services within NHS Highland and beyond.
Pharmacist actions during consultations (n=1018)
Assessed patient response and tolerability to antidepressant (27.6%)
Reviewed patient understanding and medication adherence (23.1%)
Provided patient advice on choice of treatment (9.5%)
Provided reassurance advice (9.1%)
Identified patient and medication factors relating to choice of treatment (7.6%)
Increased antidepressant dose (7.6%)
Started antidepressant (5.2%)
Provided Decider Skills (proactive mental health CBT) (2.9%)
Reduced antidepressant dose (2.1%)
Stopped antidepressant (2.1%)
